I expect CXS will be seeking tissue samples (if available) on these 35% of patients on the pivotal trial if indeed they don't already have them, in order to confirm their T315I status. While I have no intimate knowledge of the clinical trial other than what has been made public, it would be standard medical (Haematological Oncology) practice to have retained blood samples or bone marrow biopsy results from the patients on the trial. Consent would have been obtained from the trial participants to use these tissue samples.
- Forums
- ASX - By Stock
- CXS
- t315i mutation testing
t315i mutation testing , page-8
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CXS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online